IMV Inc (IMV.CA) Stock Price & Overview
TSX:IMV • CA44974L3011
The current stock price of IMV.CA is 1.12 CAD. Today IMV.CA is down by -1.75%. In the past month the price increased by 55.56%. In the past year, price decreased by -92.91%.
IMV.CA Key Statistics
- Market Cap
- 13.117M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.19
- Dividend Yield
- N/A
IMV.CA Stock Performance
IMV.CA Stock Chart
IMV.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IMV.CA. When comparing the yearly performance of all stocks, IMV.CA is a bad performer in the overall market: 99.11% of all stocks are doing better.
IMV.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMV.CA. Both the profitability and financial health of IMV.CA have multiple concerns.
IMV.CA Earnings
IMV.CA Forecast & Estimates
7 analysts have analysed IMV.CA and the average price target is 28.69 CAD. This implies a price increase of 2461.38% is expected in the next year compared to the current price of 1.12.
For the next year, analysts expect an EPS growth of 20.34% and a revenue growth -80.66% for IMV.CA
IMV.CA Groups
Sector & Classification
IMV.CA Financial Highlights
Over the last trailing twelve months IMV.CA reported a non-GAAP Earnings per Share(EPS) of -6.19. The EPS increased by 4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMV.CA Ownership
IMV.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 649.69M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 383.254M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 158.87M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 68.396M | ||
| COV | COVALON TECHNOLOGIES LTD | 12.9 | 51.373M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 37.483M | ||
| RVX | RESVERLOGIX CORP | N/A | 35.965M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 3.25 | 31.867M | ||
| HEM | HEMOSTEMIX INC | N/A | 15.62M | ||
| MPH | MEDICURE INC | N/A | 10.127M | ||
| CSCI | COSCIENS BIOPHARMA INC | N/A | 6.392M | ||
| KNE | KANE BIOTECH INC | N/A | 6.356M | ||
| QPT | QUEST PHARMATECH INC | N/A | 5.92M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find more growth stocks the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About IMV.CA
Company Profile
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
Company Info
IMV Inc
130 Eileen Stubbs Ave Suite 19
Dartmouth NOVA SCOTIA B3B 2C4 CA
CEO: Frederic Ors
Employees: 63
Phone: 19024921819.0
IMV Inc / IMV.CA FAQ
What does IMV Inc do?
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
What is the stock price of IMV Inc today?
The current stock price of IMV.CA is 1.12 CAD. The price decreased by -1.75% in the last trading session.
Does IMV Inc pay dividends?
IMV.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMV stock?
IMV.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is IMV Inc (IMV.CA) expected to grow?
The Revenue of IMV Inc (IMV.CA) is expected to decline by -80.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is IMV Inc worth?
IMV Inc (IMV.CA) has a market capitalization of 13.12M CAD. This makes IMV.CA a Nano Cap stock.
Can you provide the ownership details for IMV stock?
You can find the ownership structure of IMV Inc (IMV.CA) on the Ownership tab.